FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

Disclosure: R. Douglas: Consulting Fee; Self; Horizon Therapeutics, Viridian Therapeutics. Research Investigator; Self; Viridian Therapeutics Inc., Horizon Therapeutics. S. Ugradar: Consulting Fee; Self; Viridian Therapeutics Inc. K. Cockerham: Advisory Board Member; Self; Viridian Therapeutics Inc....

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond, Ugradar, Shoaib, Cockerham, Kimberley, Eric Turbin, Roger, Tang, Rosa, Nijhawan, Navdeep, O’Shaughnessy, Denis J, Summerfelt, Rochelle M, She, Angela, Katz, Barrett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555352/
http://dx.doi.org/10.1210/jendso/bvad114.1890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555352/
http://dx.doi.org/10.1210/jendso/bvad114.1890

Ejemplares similares